Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

Short- and Longterm Results After Intravesical Injection of Botulinum Neurotoxin Type A for Treating Therapy Refractory Overactive Bladder in Females - a Retrospective Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01042119

Enrollment

200

Registered

2010-01-05

Start date

2010-01-31

Completion date

2010-06-30

Last updated

2010-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder Syndrome

Keywords

botulinum neurotoxin type A, BoNT/A, Botox, overactive bladder syndrome

Brief summary

The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle. The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* intravesical treatment with Botox at our clinic

Design outcomes

Primary

Measure	Time frame
duration of effect of Botox	1 year

Countries

Switzerland

Outcome results